Replies to post #1899 on Vascular Biogenics Ltd (VBLT)

[sys483]

I imagine others will be also be second guessing the P3 trial protocol. I sure would liked to have seen VB-111 as a monotherapy verse Avastin alone in a head-to-head trial. Analysis of the full data when it’s available should be very revealing.

I went back to compare the Phase 2. It’s interesting to note the difference between the P2 and P3 trials. In the P2 trial all patients received VB-111 as monotherapy until disease progression at which point they were split between VB-111 with Avastin and Avastin alone. Could the extra doses of VB-111 while on monotherapy have made the difference?

wcopeland, I agree with you about Dror. I think he was very forthcoming about the results, in what must have been an extremely difficult situation. For us it has turned into a bad investment, but Dror has spent the better part of his career developing VB-111. This has got to be somewhat devastating for him. I also wonder what’s going to happen with their brand new drug manufacturing facility. It looked like such a good idea at the time. Now it almost looks like a white elephant. And what about all the recent additions to their headcount? Will they keep all those new employees?

I was hoping this stock was going to help my retirement, but there are others who were hoping it was going to help them live longer. Lots of disappointment all around.